Exclusive Chinese patent medicine explodes the tens of billions of stomach disease market!

With the acceleration of the pace of life, the incidence of gastric diseases is increasing year by year, and Chinese patent medicines for the treatment of gastric diseases are gradually favored by patien.

Figure 1: The market size of Chinese patent medicine stomach medicine (gastritis, ulcer) in the past three years (unit: 100 million yuan)

Source: Mi intranet database

From the perspective of channel proportion, the proportion of terminals in China's public medical institutions (including urban public hospitals, county-level public hospitals, urban community centers and township health centers) has remained above 70%, which is the main competition area; China's urban physical pharmacies Terminals account for about 25%, and with the active promotion of online sales of prescription drugs, the proportion of online pharmacy terminals in China is also rising rapid.

Medical terminal: Yangzijiang seizes the high position, and Lifang Pharmaceutical's "ultra-high-speed" growth

In 2021, the terminal Chinese patent medicine gastric medicine market of public medical institutions in China will exceed 4 billion yuan, with a growth rate of more than 10%, which is the highest value in the past five yea.

In 2021, Yangzijiang Jiangsu Pharmaceutical's sales in the Chinese patent medicine stomach medicine market exceeded 2 billion yuan for the first time, and it is the only company exceeding 1 billion yu.

Table 1: Top 10 brands of Chinese patent medicine stomach medicine (gastritis, ulcer) in China's public medical institutions in 2021

Source: Min.

In 2021, there are 18 brands of Chinese public medical institutions with terminal Chinese patent medicine gastric medicine sales exceeding 100 million yu.

Figure 2: Sales of two exclusive products of Yangtze River (unit: 100 million yuan)

Source: Min.

Weisu Granules is a new traditional Chinese medicine developed by Yangzijiang in 1993 according to the prescription offered by Professor Tung Chee-hwa, the master of traditional Chinese medicine, which can effectively improve the symptoms of stomach bloating and stomach pa.

Diling Weitong Granules are made from the ancient prescription Jinlingzi Powder and Zuojinwan, and are used to treat chronic gastritis, peptic ulcer, functional dyspepsia and other diseas.

In 2021, there is also a "potential bomb" in the TOP20 brands of Chinese patent medicine stomach medici.

Brick-and-mortar pharmacies: China Resources Sanjiu remains the champion, and Lingrui paste is on the list

In 2021, the market size of Chinese patent medicine gastric medicines in urban physical pharmacies will be close to 7 billion yuan, with a growth rate of 24%, slightly lower than the growth rate of public medical institutio.

Sichuan Good Doctor Panxi Pharmaceutical has maintained a positive growth trend in the physical pharmacy termin.

Table 2: Top 10 brands of Chinese patent medicine stomach medicine (gastritis, ulcer) in Chinese urban physical pharmacies in 2021

Source: Minenet Chinese city physical pharmacy terminal

Note: sales below 100 million yuan are indicated by *

In 2021, there are 4 brands of Chinese patent medicine stomach medicine with sales of more than 100 million yuan in Chinese urban physical pharmacies, and the threshold for TOP10 brands is 50 million yuan, including Sanjiuweitai granules, Weisu granules, Biling Weitong granules, and Weizheng granul.

Sanjiu Weitai Granules of China Resources Sanjiu Medicine are used to treat stomach pain caused by damp-heat, qi stagnation and blood stasis, and superficial gastrit.

The only patch in the TOP10 brand is Henan Lingrui Pharmaceutical's Shufu patch, which is used to treat epigastric pa.

In addition, Rongchang Pharmaceutical (Zibo)'s Shugan and Wei Wan entered the TOP20 brands for the first time in 2021, with growth rates of 98%, 67%, and 93% respectively in the last three yea.

Online pharmacy: Chen Liji of Baiyun Mountain counterattacked the king, and the three major brands soared by more than 100%

In 2021, China's online pharmacy terminal Chinese patent medicine gastric medicine market will be around 260 million yuan, with a growth rate of 69%, far exceeding the growth rate of public medical institution terminals and urban physical pharmacy termina.

From 2020 to 2021, Baiyunshan Chenliji Pharmaceutical Factory will soar to the top with a growth rate of 561% and 263% respectively, and its market share will rise to 12%, while Handan Pharmaceuticals and Sichuan Good Doctor Panxi Pharmaceuticals will be ranked second and third in 202 The market share of all companies exceeds 10%, and the total share of TOP3 companies is 3

Table 3: Top 10 brands of Chinese patent medicine stomach medicine (gastritis, ulcer) in China's online pharmacy terminal in 2021

Source: Minet China Online Pharmacy Terminal

Note: sales below 10 million yuan are indicated by *

In 2021, there are 4 brands of Chinese patent medicine stomach medicine with sales of more than 10 million yuan in China's online pharmacy terminals, and the threshold for TOP10 brands is 5 million yuan, including Weiyangning Pills, Yangweishu Granules, Morodan (concentrated pills), three Jiuweitai Granules, Morodan, Heweizhengchang Pills and Hericium Hericium Extract Granules are exclusive produc.

Figure 3: Three exclusive products with sales exceeding 10 million yuan (unit: 10,000 yuan)

Source: Minet China Online Pharmacy Terminal

The Weiyangning Pills of Baiyunshan Chenli Jiyao are used for epigastric distention or tingling, vomiting and pantothenic ac.

The Yangweishu Granules of Hefei China Resources Shenlu Pharmaceutical have anti-inflammatory and analgesic properties, improve gastric acid secretion, enhance digestive function, and enhance immune functi.

Handan Pharmaceutical's Morodan (concentrated pill) is used for chronic atrophic gastrit.

The growth rate of the three exclusive products in China's online pharmacy terminals will exceed 100% in 202

New Deal dividends are here, and the future of new gastric and traditional Chinese medicine drugs

On December 31, 2021, NMPA approved the launch of Jianmin Pharmaceutical Group's 1 class innovative drug Qirui Weishu Capsu.

The new drug is an innovative traditional Chinese medicine drug developed on the basis of preparations in medical institutio.

Treatment of epigastric pain caused by moderate chronic non-atrophic gastritis with erosive damp-heat stasis syndro.

Jianmin Pharmaceutical Group mentioned in the announcement that the total investment in research and development of Qiriweishu Capsules exceeded 27 million yu.

Qirui Weishu Capsule is the first class 1 new drug of traditional Chinese medicine for stomach diseases approved for marketing in the past ten yea.

On April 29, 2022, the CDE official website publicly solicited opinions on the "Guidelines for the Evaluation of Clinical Efficacy of New Traditional Chinese Medicines for Chronic Gastritis" and "Guidelines for the Evaluation of Clinical Efficacy of New Traditional Chinese Medicines for Gastroesophageal Reflux Disease", which are mentioned in the drafting instructio.

The above principles are expected to guide the research and development of new traditional Chinese medicines for chronic gastritis and gastroesophageal reflux to highlight the advantages and characteristics of traditional Chinese medicine treatme.

Table 4: Some of the new Chinese medicines for gastric diseases currently undergoing clinical trials (above phase II)

Source: Minet China Drug Clinical Trials Publicity Library

Most of the new traditional Chinese medicines for stomach diseases currently undergoing clinical trials are products that obtained clinical approval before 201 Jiangxi Qingfeng Pharmaceutical's Orantiweikang Tablet is currently the fastest-growing product, and the road to research and development of this new drug is also quite Tortuous, the earliest clinical approval was obtained in 2008, the phase III clinical trial for functional dyspepsia was completed in 2014, and it was declared for listing in 201 The functional dyspepsia postprandial discomfort syndrome (Qi stagnation syndrome) was launched in 201 Phase II clinic.

It can be seen that there are still many difficulties and bottlenecks in the research and development of new Chinese medicines for stomach diseas.

With the continuous improvement of patients' needs, under the new guiding principles, enterprises may be able to take less detou.

With the joint efforts of the government and enterprises , the tens of billions of gastroenterology Chinese medicine market will also usher in a new situation in the futu.